ArticleOncotarget2018
Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic "dual-hit" option.
Peter Dietrich et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
21 papers cite it
this papercites it